Full text

Turn on search term navigation

© 2022. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Introduction

People with type 2 diabetes have increased risk of dementia. Glucagon‐like peptide‐1 (GLP‐1) receptor agonists (RAs) are among the promising therapies for repurposing as a treatment for Alzheimer's disease; a key unanswered question is whether they reduce dementia incidence in people with type 2 diabetes.

Methods

We assessed exposure to GLP‐1 RAs in patients with type 2 diabetes and subsequent diagnosis of dementia in two large data sources with long‐term follow‐up: pooled data from three randomized double‐blind placebo‐controlled cardiovascular outcome trials (15,820 patients) and a nationwide Danish registry‐based cohort (120,054 patients).

Results

Dementia rate was lower both in patients randomized to GLP‐1 RAs versus placebo (hazard ratio [HR]: 0.47 (95% confidence interval [CI]: 0.25–0.86) and in the nationwide cohort (HR: 0.89; 95% CI: 0.86–0.93 with yearly increased exposure to GLP‐1 RAs).

Discussion

Treatment with GLP‐1 RAs may provide a new opportunity to reduce the incidence of dementia in patients with type 2 diabetes.

Details

Title
Treatment with glucagon‐like peptide‐1 receptor agonists and incidence of dementia: Data from pooled double‐blind randomized controlled trials and nationwide disease and prescription registers
Author
Nørgaard, Caroline Holm 1 ; Friedrich, Sarah 2 ; Hansen, Charlotte Thim 3 ; Gerds, Thomas 4 ; Ballard, Clive 5 ; Møller, Daniel Vega 3 ; Knudsen, Lotte Bjerre 6 ; Kvist, Kajsa 3 ; Zinman, Bernard 7 ; Holm, Ellen 8 ; Torp‐Pedersen, Christian 9   VIAFID ORCID Logo  ; Mørch, Lina Steinrud 3 

 Department of Cardiology and Clinical Research, Nordsjællands University Hospital, Hillerød, Denmark, Department of Medicine, University of California Irvine, Irvine, California, USA 
 Department of Medical Statistics, University Medical Center Göttingen, Göttingen, Germany 
 Novo Nordisk, Søborg, Denmark 
 Section of Biostatistics, Copenhagen University, Østerbro, Denmark 
 St Luke's Campus, University of Exeter College of Medicine and Health, Exeter, UK 
 Novo Nordisk, Måløv, Denmark 
 Lunenfeld–Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada 
 Department of Medicine, Nykøbing Falster Hospital, Hospitalsvej, Nykøbing Falster, Denmark 
 Department of Cardiology and Clinical Research, Nordsjællands University Hospital, Hillerød, Denmark, Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark 
Section
RESEARCH ARTICLES
Publication year
2022
Publication date
2022
Publisher
John Wiley & Sons, Inc.
ISSN
23528737
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2758349074
Copyright
© 2022. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.